NASDAQ · COCH
Healthcare · Medical - Devices
$0.65
Down-$0.05 (-7.91%)
Updated Oct 22, 2026, 8:47 PM
SID Score
2.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · COCH
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 21, 2026
COCH closed at $0.65 after 21 trading sessions, down 10.37% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 21, 2026 | $0.6393 | $0.6804 | $0.6345 | $0.6471 | 72.21K |
| Oct 20, 2026 | $0.6574 | $0.6892 | $0.6258 | $0.6345 | 155.78K |
| Oct 19, 2026 | $0.65 | $0.6774 | $0.6272 | $0.654 | 104.42K |
| Oct 16, 2026 | $0.659 | $0.6693 | $0.6442 | $0.668 | 41.34K |
| Oct 15, 2026 | $0.6201 | $0.6447 | $0.61 | $0.6447 | 47.99K |
| Oct 14, 2026 | $0.65 | $0.66 | $0.62 | $0.6373 | 104.96K |
| Oct 13, 2026 | $0.669 | $0.6699 | $0.65 | $0.6594 | 47.15K |
| Oct 12, 2026 | $0.655 | $0.6699 | $0.6381 | $0.6515 | 139.17K |
| Oct 9, 2026 | $0.66 | $0.6705 | $0.652 | $0.6578 | 34.81K |
| Oct 8, 2026 | $0.6638 | $0.67 | $0.65 | $0.6576 | 30.69K |
| Oct 7, 2026 | $0.67 | $0.67 | $0.65 | $0.6534 | 76.55K |
| Oct 6, 2026 | $0.67 | $0.67 | $0.6511 | $0.6512 | 57.46K |
| Oct 5, 2026 | $0.6657 | $0.685 | $0.65 | $0.651 | 73.31K |
| Oct 2, 2026 | $0.684 | $0.6999 | $0.654 | $0.678 | 160.58K |
| Oct 1, 2026 | $0.683 | $0.7049 | $0.6541 | $0.6606 | 73.61K |
| Sep 30, 2026 | $0.71 | $0.71 | $0.6804 | $0.6811 | 31.47K |
| Sep 29, 2026 | $0.70 | $0.715 | $0.6806 | $0.709 | 58.31K |
| Sep 28, 2026 | $0.702 | $0.7066 | $0.69 | $0.6921 | 64.87K |
| Sep 25, 2026 | $0.6904 | $0.7284 | $0.6904 | $0.715 | 55.05K |
| Sep 24, 2026 | $0.7291 | $0.7385 | $0.7001 | $0.7161 | 39.56K |
| Sep 23, 2026 | $0.7183 | $0.73 | $0.715 | $0.722 | 33.57K |
The latest Smart Investors Daily articles mentioning COCH.
Company
Market Activity
Research & News
COCH research
Company profile and research snapshot.
Envoy Medical Inc is a hearing health company focused on providing medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life. The Company has one reportable segment: hearing. The hearing segment derives revenue from the sale of the Esteem FI-AMEI implants and replacement components to Esteem FI-AMEI implants.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 6, 2026 | Lake Street | Buy | — |
| Aug 21, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 27, 2026 | LUCID CAPITAL MARKETS | Buy | — |
| Jul 15, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 31, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Oct 12, 2026
Second of Four Planned Modules Moves Rolling FDA Review ForwardAdvances Toward Targeted Completion of the Final Clinical Module Submission in Q2 2027White Bear Lake, Minnesota--(Newsfile Corp. - October 12, 2026) -
Benzinga · Oct 7, 2026
On October 6, 2026, Envoy Medical, Inc., a Delaware corporation (the "Company"), entered into a Dismissal Agreement (the "Dismissal Agreement") regarding litigation in the Delaware Court of Chancery (the
Benzinga · Oct 6, 2026
Lake Street analyst Frank Takkinen initiates coverage on Envoy Medical (NASDAQ:COCH) with a Buy rating and announces Price Target of $2.5.
Benzinga · Sep 22, 2026
Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced the grant of two additional international
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning COCH.
